Piper Sandler raised the firm’s price target on Viatris (VTRS) to $14 from $13 and keeps a Neutral rating on the shares following the firm’s annual healthcare conference. Piper continues to believe that to the extent that Viatris is going to see multiple expansion over time, it will take clinical/regulatory success on “innovative” brand assets.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio